Cytyc and TriPath rush for share of UK LBC (liquid-based cytology) pie
This article was originally published in Clinica
Cytyc's monopoly of the US liquid-based cytology (LBC) market is likely to be mirrored in the UK as the country's conversion to LBC for cervical cancer screening begins to gather momentum, analysts predict.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.